BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 1713065)

  • 1. Prostate cancer-associated markers.
    Chu TM
    Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic markers and the diagnosis of prostatic cancer.
    Ban Y; Wang MC; Chu TM
    Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
    Yoshiki T; Okada K; Oishi K; Yoshida O
    Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
    Mulders TM; Bruning PF; Bonfrer JM
    Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
    Bauer HW
    Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
    Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
    Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged.
    Jenkins D; Jones RT; Clarke AM
    Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
    Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
    Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The laboratory diagnosis of prostatic adenocarcinoma.
    Griffiths JC
    Crit Rev Clin Lab Sci; 1983; 19(3):187-204. PubMed ID: 6144453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization of prostate carcinoma-associated antigens.
    Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
    Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinoma of the prostate: biopsy to whole mount. Denver VA experience.
    Donohue RE; Miller GJ
    Urol Clin North Am; 1991 Aug; 18(3):449-52. PubMed ID: 1715102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
    Beckett ML; Lipford GB; Haley CL; Schellhammer PF; Wright GL
    Cancer Res; 1991 Feb; 51(4):1326-33. PubMed ID: 1705172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen].
    Mathieu MC; Caillaud JM
    Bull Cancer; 1985; 72(5):405-13. PubMed ID: 2416371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
    Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schistosomiasis, metaplasia and squamous cell carcinoma of the prostate: histogenesis of the squamous cancer cells determined by localization of specific markers.
    Al Adnani MS
    Neoplasma; 1985; 32(5):613-22. PubMed ID: 2415839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
    Svanholm H; Hørder M
    Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen. Experimental and clinical observations.
    Huber PR; Schnell Y; Hering F; Rutishauser G
    Scand J Urol Nephrol Suppl; 1987; 104():33-9. PubMed ID: 2449722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.